Drugmaker Daiichi Sankyo Co. won approval to sell the antibiotic Gracevit in its home market.
The Health, Labor and Welfare Ministry approved Gracevit as a broad-spectrum antibacterial agent on Friday, Tokyo-based Daiichi said in a statement on its Web site Monday. The medicine, which may be prescribed as a new quinolone oral antibacterial agent, is approved in 50-mg doses and in powder form, the company said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.